Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Dec. 31, 2025
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Item 9B. Other Information. (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. None. (b) Insider trading arrangements and policies. On December 19, 2025, Kevin Craig, the Company’s Chief Medical Officer, entered into a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Craig 10b5-1 Plan”). The Craig 10b5-1 Plan provides for the periodic sale of up to 440,316 shares of common stock until December 31, 2026. Other than the foregoing, during the quarter ended December 31, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K. |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Kevin Craig [Member] | |
| Trading Arrangements, by Individual | |
| Name | Kevin Craig |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | December 19, 2025 |
| Aggregate Available | 440,316 |